Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
Nature Communications|July 6, 2024
An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responsesWeiqi Zhang, Yinghua Zeng, Qiuqun Xiao, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|June 16, 2004
[The mechanism of topotecan resistance in ovarian cancer cell line]Ping Jia, Shao-Bo Wu, Fang Li, et al.
Food & Function|January 13, 2025
Modification of Ganoderma lucidum spore shells into probiotic carriers: selective loading and colonic delivery of Lacticaseibacillus rhamnosus and effective therapy of inflammatory bowel diseaseNing Liao, Juan Wang, Guanwen Liu, et al.
Zhonghua Yi Xue Za Zhi|April 16, 2014
[Prediction value for dynamic changes of circulating tumor cell in therapeutic response and prognosis of Chinese metastatic breast cancer patients]Li Bian, Yi Liu, Tao Wang, et al.
Gene|July 26, 2020
The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancerLiping Guo, Bo Chen, Guochun Zhang, et al.
Frontiers in Pharmacology|June 8, 2023
Corrigendum: Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: a real-world comparative cohort studyYu-Ning Liao, Hsing-Yu Chen, Ching-Wei Yang, et al.
AI Zheng = Aizheng = Chinese Journal of Cancer|December 25, 2003
[Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]Ping Jia, Shao-Bo Wu, Qian Xu, et al.
Molecular Nutrition & Food Research|June 26, 2015
Calebin-A inhibits adipogenesis and hepatic steatosis in high-fat diet-induced obesity via activation of AMPK signalingChing-Shu Lai, Sih-Ning Liao, Mei-Ling Tsai, et al.
Integrative Medicine Research|July 25, 2026
Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation studyYu-Ning Liao, Tsung-Hsien Yang, Yi-Chin Lu, et al.
Pathology, Research and Practice|November 25, 2010
HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS componentNing Liao, Guo-chun Zhang, Yan-hui Liu, et al.
Pageof 18